|Year : 2020 | Volume
| Issue : 1 | Page : 140-146
Vitiligo with special emphasis on vitiligo surgery
PK Ashwini, DJ Sushmitha, S Veeranna
Department of Dermatology, Venereology and Leprology, JSS Medical College, JSS Academy of Higher Education and Research, Mysuru, Karnataka, India
|Date of Submission||07-Apr-2020|
|Date of Decision||15-May-2020|
|Date of Acceptance||19-May-2020|
|Date of Web Publication||20-Jun-2020|
Dr. P K Ashwini
Department of Dermatology, Venereology and Leprology, JSS Medical College, JSS Academy of Higher Education and Research, Mysuru, Karnataka
Source of Support: None, Conflict of Interest: None
Vitiligo is a common form of localized depigmentation. It is an acquired hypomelanotic condition resulting from the progressive loss of melanocytes. It is characterized by milky white macules. It can be associated with tremendous psychological trauma. A number of medical treatment options exist in the armamentarium of a dermatologist treating vitiligo. However, a significant number of lesions of vitiligo either fail to respond to medical therapy or respond with incomplete repigmentation. Such lesions are considered appropriate for surgical management. Surgical management has provided a very good tool to the management of refractory cases of vitiligo. Hence, in this article, we emphasize on vitiligo and vitiligo surgery.
Keywords: Melanocytes, vitiligo, vitiligo surgery
|How to cite this article:|
Ashwini P K, Sushmitha D J, Veeranna S. Vitiligo with special emphasis on vitiligo surgery. Arch Med Health Sci 2020;8:140-6
| Introduction|| |
Vitiligo is a very common, acquired, pigmentary disorder of skin and hair characterized by the appearance of white patches on the skin and mucosa. It occurs due to the autoimmune destruction of functional melanocytes (MC). Incidence in the racially pigmented skin is much higher. Vitiligo has been derived from the Latin word “vitium” meaning “blemish.” Alternatively, the Latin derivation may be from the white, glistening flesh of calves. By 1450 BC, white leprosy spots were called as “swetha kushtha” in the Atharva veda and in 1200 BC, Japanese Shinto prayers described the similar condition in the “Amarakosa.” The term 'Vitiligo' was first said to be used by Celsus in his Latin medical classic 'De Medicina in 1st century AD.
The World Vitiligo Day is observed on June 26. This day signifies spreading the knowledge regarding the various treatment options and counseling the public and the patients regarding the stigma associated with the condition. The Indian Association of Dermatologist, Venereologist and Leprologists (IADVL) conducts various public awareness programs on this day such as street plays, seminars, and awareness talks.
| Epidemiology|| |
The worldwide prevalence of vitiligo ranges from 0.4% to 2.0%, with the highest incidence being recorded in India, followed by Mexico and Japan., The prevalence of vitiligo has been reported to be between 0.25% and 4% of dermatology outpatients across studies from India. Vitiligo affects both genders, and the mean age of onset is before 20 years in case of childhood vitiligo but varies between 18 and 32 years in adults.,
Among the multitude of triggers such as chemicals, allergens, occupation, diet, systemic illness, and sunlight implicated, the physical trauma to the skin perhaps seems to be the most implicated factor, both for onset and development of vitiligo and tendency of the lesions for localizing over trauma-prone sites (Koebner's phenomenon). The presence of Koebner's phenomenon, a very frequent occurrence in 20%–60% vitiligo patients, corroborates with this observation. The proportion of affected patients with positive family history varies in different parts of the world. In India, it ranges from 6.25% to 18%.
| Etiopathogenesis|| |
Vitiligo being a multifactorial disease has a relationship with both genetic and acquired factors. Family and twin studies points toward the importance of genetic factors in the development of vitiligo., Many of these genes are involved in melanogenesis, immune regulation, and apoptosis. In vitiligenous skin, there is loss or disappearance of epidermal or follicular MC. The MCs in vitiligo skin are susceptible to environmental triggers or stressors. Ultimately, there is development of autoimmunity which is directed against MC.
Autoimmunity has always been suspected to play a significant role in the pathogenesis of vitiligo. An alteration in immune surveillance has been proposed as the significant primary event leading to dysfunction and destruction of MC.
According to this hypothesis, destruction of MC occurs due to liberation of some unusual neurochemical mediator or a gross alteration in the ratio of the normal neurotransmitter levels in the lesion. This could be due to the common origin of both the MC and nerves arising from the neural crest cells.,
Free radical hypothesis
The oxidative stress theory suggests that the intra -epidermal accumulation of reactive oxygen species, the most notorious one being hydrogen peroxide (H2O2), lead to the destruction of melanocytes.
Other proposed theories include low circulating growth factors, Vitamin D deficiency, and melanocytorrhagy.,,,,
| Clinical Features|| |
Vitiligo is characterized by the appearance of patchy discoloration of the skin in the form of typical chalky-white or milky skin lesions. The macules are round or oval in shape with sizes ranging to few millimeters to a foot or more. Lesions affect the skin and mucous membranes. They are asymptomatic although itching or burning may precede or accompany the onset of vitiligo.,,,
Sites commonly affected are pretibial area, knees, sides of ankles, elbows, and skin overlying the digits. Periorificial areas such as the circumoral, anogenital and periocular areas are also affected. Leukotrichia (gray hairs) is a common feature of vitiligo lesions, especially on hair-bearing skin. It has diagnostic and prognostic significance. Diagnostic significance implies that it helps in differentiating it from other hypopigmented macules. Prognostic significance indicates a poor repigmenting capacity.
[TAG:2]Classification of Vitiligo [/TAG:2]
There is no universally accepted classification available for vitiligo.
- Focal vitiligo: One or more macules in one area, but not in a segmental distribution
- Unilateral or segmental vitiligo: One or more macules involving a unilateral segment of the body and the lesions stop abruptly at the midline
- Mucosal vitiligo: Mucous membranes alone.
- Vitiligo vulgaris: Scattered patches that are widely distributed
- Vitiligo acrofacialis: Seen on distal extremities and face
- Mixed vitiligo: Mixture of acrofacialis and vulgaris.
Complete or nearly complete depigmentation.
There is complete absence of melanin granules in the vitiligenous skin. Histochemical studies show gross lack of dihydroxy phenylalanine-positive MC in the basal layer. The special stain used for melanin is Mason Fontana stain.
| Associations of Vitiligo|| |
Cutaneous associations: Leukotrichia, premature graying of the hair, and other conditions such as lichen planus, alopecia areata, and halo nevus, are frequently reported cutaneous associations.,
| Systemic Associations|| |
Systemic diseases such as pernicious anemia, thyroid disorders, diabetes mellitus, Addison's disease, and autoimmune polyendocrinopathy are a few of the systemic conditions associated with vitiligo.
| Course of the Disease|| |
The course of vitiligo is very unpredictable and uncertain. Lesions might remain static/same for an indefinite period after a certain degree of regional extension. In vitiligo vulgaris, lesions can develop on several different areas in succession. At times, the repigmented spots occur spontaneously. Complete spontaneous cure is extremely rare.
| Management|| |
There is no ideal treatment for vitiligo as the exact pathogenesis of the disease is still elusive. Earliest of the therapies or treatment modalities that were available was from various indigenous folk medicines. They were used in different countries. It comprised of an oily extract from the seeds of Psoralea corylifolia.
Current treatment options for vitiligo include medical, surgical, and adjunctive treatments. They range from topical corticosteroids (TCS), topical calcineurin inhibitors (TCIs), ultraviolet (UV)-based therapy (narrowband [NB]-UVB, targeted phototherapy, and psoralen and UVA photochemotherapy), to multiple surgical treatments – punch grafting, suction blister grafting, and melanocyte keratinocyte transplantation. Medical treatment mainly targets the immune system. It helps in arresting the spread of depigmentation.
| Topical Corticosteroids|| |
These are often used as the first-line therapy for localized disease. When TCS are used over 2–4 months, it yields good results, but side effects may develop such as atrophy, hypertrichosis, and in cases, treatment needs to be interrupted. When applied over eyelids, additional side effects such as increased intraocular pressure and glaucoma call for extra caution.
| Topical Calcineurin Inhibitors|| |
Among the various medical treatment options, TCIs such as tacrolimus and pimecrolimus are recommended as one of the first-line treatments for localized forms of vitiligo. Combining TCIs with phototherapy has definitely shown to enhance the treatment response.
| Phototherapy|| |
Phototherapy is the use of UV radiation or visible light for therapeutic purposes. UV radiation is a small component of the electromagnetic spectrum with a NB of radiation from 200 to 400 nm.
Psoralen ultraviolet A photochemotherapy
Consumption of psoralen tablets followed by UV A-320–400 nm (PUVA) has shown a beneficial effect in vitiligo. The plant origin widely used is 8-methoxy psoralen. The synthetic drug 4, 5, 8-trimethyl psoralen, which is less phototoxic after oral administration, is primarily used for treatment of vitiligo. In a similar manner, PUVASOL can be given where psoralen with sunlight is used as a source of UVA rays. The disadvantage here is the difficulty in quantifying UV light. It can be used to induce pigmentation over streaks of residual depigmentation left after grafting. Topical application of 8 methoxy psoralen followed by sun exposure is advised for three to four times per week.,
Narrow band (311 nm) UVB phototherapy
Just like the PUVA therapy, NB-UVB may exert its effects in vitiligo through a two-step process. First being the stabilization of the depigmenting process and the second being the stimulation of residual follicular MC. Fluorescent bulbs that deliver UVB in the range of 310–315 nm are used.
It involves application of light energy directly on the lesion through special delivery mechanisms such as fiberoptic cables. The term “targeted phototherapy” includes different technologies such as excimer laser (308 nm), intense pulse light systems, and nonlaser UV light sources with improved hand-held delivery systems.
Azathioprine, levimasole, antioxidants, oral corticosteroids are used. Oral minipulse is a type of pulse steroid therapy where oral betamethasone 5 mg daily for 2 consecutive days has also been used to treat resistant and extensive disease with variable results. It helps to control the progression of rapidly spreading disease. The patients need to be monitored for development of steroid-induced side effects like weight gain and acne form eruptions. Also, low-dose oral mini pulse dexamethasone 2.5 mg/day on 2 consecutive days per week is found to be beneficial for arresting progressive unstable vitiligo with minimal adverse effects.
[TAG:2]Surgical Thérapies ,,[/TAG:2]
Surgery for vitiligo is useful in resistant areas and residual lesions. The choice of surgical treatment depends on the type of vitiligo; stability, extent, and site of lesions; the availability of equipment; and expertise of the treating surgeon. The various procedures include surgical excision, dermabrasion, punch grafting, micropigmentation, minigrafting, thin thiersch grafting, epidermal grafting, and transplantation of in vitro cultured epidermis bearing MC.
| Principle of Vitiligo Surgery|| |
All surgical techniques for vitiligo rely on the one basic principle; when melanocyte reservoir is lost in the epidermis, repopulating with functional MC from normally pigmented epidermis or hair follicles. The MCs which have been introduced will then establish and function as epidermal melanin units.
| Parameter for Patient Selection|| |
- Duration of stability
- Test grafting
- Keobner's phenomenon
- Longevity of stability
- Disease versus lesional stability.
| Stability in Vitiligo|| |
It is mandatory that all surgeries are done after establishing stability of the disease. It indicates the absence of development of new patches and absence of increase in size of the existing patches. Absence of Keobner's phenomenon should also be considered for labeling it as stable vitiligo. Though there is lack of agreement regarding duration of stability, a period of 1 year is best followed as per the recommendations by IADVL taskforce for standard guidelines of care for dermatological procedures. Lesional stability can be considered before considering the patient for surgical techniques. A stable patch has well-defined borders in comparison with un stable patch which shows ill-defined borders. Hypomelanotic lesions with poorly defined borders indicate active lesions compared to patches which are amelanotic with sharply defined borders 
Scoring system in vitiligo:
- Vitiligo Area Severity Index – In this scoring system, the percentage of vitiligo involvement is calculated in terms of hand unit and the degree of pigmentation is estimated to the nearest of percentages [Annexure 1]
- Vitiligo Disease Activity Score – It is a 6-point scale for assessing vitiligo activity. The scoring is based on the individual own opinion of present disease activity [Annexure 2].
| Dermoscopy|| |
Dermoscopy shows white structureless areas and reduced pigment network in Vitiligo. White structureless areas appear to “glow” due to total loss of MC in the epidermis. A vitiligo patch is considered stable in the presence of sharp border, absent pigment network, reticulate pigment network, perilesional hyperpigmentation, and perifollicular pigmentation and in the absence of satellite lesions and micro Keobner's phenomenon. A cutoff score of more than or equal to 1.5 using the “BPLeFoSK criteria” is recommended.,
| Surgical Methods|| |
The methods of vitiligo grafting are divided into tissue grafting and cellular grafting. Tissues such as epidermal-dermal mini punches, ultra-thin skin layers, epidermal roof of a blister, or hair follicles are used as the sources of MC. Cellular grafts include cultured or noncultured melanocyte grafts.
- Mini punch grafting
- Suction blister grafting
- Thin split-thickness grafting
- Hair follicle grafts
- Smash grafts
- Mesh grafts.
- Noncultured cell suspensions – epidermal cell and follicular cell
- Cultured MC/keratinocytes grafts.
[TAG:2]Patient Selection [/TAG:2]
Surgery is indicated for patients with stable vitiligo patches. It can be considered in patients who are unresponsive to medical treatment. Younger patients respond better. Concurrent need for medical therapy and phototherapy postsurgery should be emphasized. Patient counseling is of utmost importance. Patients with an unrealistic expectation is not a good candidate for surgery. It is important to assess the psychosocial norms of the patient.
Preprocedural investigations such as complete blood counts, blood sugar estimation, and bleeding and clotting time can be done in most of the cases.
Ideal donor site
The upper outer aspect of thigh, medial aspect of forearm, arm, abdomen, and gluteal area can be considered. For facial lesions, the postauricular area can be considered because color match is important.
The recipient area preparation can be done using manual or motorized derma abrader, ablative CO2, or fractional CO2 laser, or Erbium YAG laser, or micro needling, cryo blistering, or suction blistering. Dermabrasion must be done evenly all over the depigmented area and 2–3 mm of peri lesional normal skin. This is to prevent the development of a peri graft halo postoperatively.
Mini punch grafting 
Epidermal mini punches of 1–2 mm sizes are harvested from the normal pigmented donor site using disposable punchesm and they are transplanted into the depigmented recipient area. It is best suited for sites with irregular contours such as nipple-areola complex, palms and soles, acral areas. It is an inexpensive, simple, and easy procedure to perform with minimal requirements. Cobblestoning and polka dot appearance are usual complications causing a cosmetic unacceptability. To minimize the chances of developing a peri graft halo, the initial recipient chambers are made very close to the border of the patch. The three-layered dressing on the recipient area is removed after 4–7 days. Postgraft phototherapy is usually followed. The grafted area is expected to repigment within 3–6 months [Figure 1]. Similarly, hair follicle transplantation can be employed, especially for those patches with leukotrichia.
|Figure 1: Miniature punch grafting: Early spread of pigment seen from punch grafts|
Click here to view
Suction blister grafting 
Epidermis is harvested from donor site by prolonged negative pressure, using a 50 cc disposable syringe attached to the plunger of 20 cc syringe using a three-way cannula, resulting in a blister formation. Approximate blistering time is from 1 to 3 h. The suction causes a physiological split at dermo-epidermal junction. The roof of the blister is then transplanted on the dermabraded recipient site, leading to transfer of MC. Sites such as lips and eye lids which need thin grafts are the best suited sites. It is an inexpensive and safe procedure. Donor-site scarring is also unusual. It gives a good cosmetic result on lip. The procedure is good to be performed for facial vitiligo. It is time consuming and yields only small-sized grafts.
Ultra-thin skin grafts
They are also called split-thickness skin grafts. Epidermal layers of 0.08–0.15 mm thickness are used as tissue source for MC. A donor skin of 10%–20% larger than the recipient area is harvested using skin harvesting knife [Figure 2]. They are suitable for larger patches and covers large areas over short period of time. Uniform pigmentation can be expected in this technique [Figure 3] and [Figure 4]. Donor area healing may be delayed and postinflammatory hyperpigmentation on recipient area might occur. The initial 72 h after graft placement is crucial for graft uptake. Proper immobilization is essential after grafting. The technique demands good surgical skill. It offers cosmetically better results than mini punch grafting. Moreover, compared to other grafts mentioned above, this procedure can cover larger areas.
|Figure 2: Ultra-thin grafts harvested from donor site and placed in saline|
Click here to view
|Figure 4: Postgraft pigmentation – 6 weeks after split-thickness grafting|
Click here to view
Cellular transplantation 
These techniques such as keratinocyte melanocyte grafts offer several advantages over tissue grafts. It has shown to cover larger surface area, better color matching, and uniform repigmentation. The donor recipient area coverage is in the ratio of 1:8 to 1:10. It requires laboratory facilities, involves high cost and is time consuming.
The process involves harvesting of skin similar to ultra-thin grafting, which is later trypsinized using 0.25% trypsin-EDTA solution. The vital steps in epidermal noncultured suspension include donor harvesting, trypsinization to separate the cells, anti-trypsinization to remove excess trypsin, centrifugation to make a cell suspension, and finally transplanting the obtained suspension over the dermabraded recipient area. In 1998, Olsson and Juhlin  introduced rapid trypsinization method within 60 min under 37°C (hot trypsinization) and transplanting the cell suspension, nourished with melanocyte culture medium, directly on the dermabraded recipient site. Addition of hyaluronic acid to the cell suspension to increase viscosity and adherence to the recipient site was proposed by van Geel et al. Holla et al. modified the steps to reduce the cost of the procedure by introducing phosphate-buffered saline, as a way to circumvent the use of trypsin inhibitor.
After the procedure, the onset of pigmentation can take 3 weeks and 6 months [Figure 5] and [Figure 6]. Adjuvant therapies such as phototherapy help. Proper counseling of the patients is important as to what can be expected and also about the possible progression of the disease process.
|Figure 5: Patchy pigmentation postmedical therapy – recalcitrant patch without even repigmentation|
Click here to view
|Figure 6: Even repigmentation seen 8 weeks postgraft-noncultured epidermal suspension|
Click here to view
Autologous noncultured epidermal cell suspension is also simplified using a four-compartment method compared to the laboratory-based method. The results are comparable to the conventional method of vitiligo surgery. Combination of noncultured epidermal and dermal suspension is a novel technique. The combination technique is said to give excellent results in patients with vitiligo with shorter duration of clinical stability.
| Future Prospects in Vitiligo Therapy|| |
The discovery of melanocyte specific T memory cells leads to bringing vitiligo under memory skin disease. Future therapies should goal at blocking the differentiation and/or their accumulation in vitiligo skin. It is suggested to use TCIs as maintenance therapy in repigmented patches to prevent their loss of pigmentation. Systemic immunomodulating agents could be another strategy for patients with higher body surface area. In addition, steroid-sparing immunomodulating agents that could be used for mid and/or long-term period, such as methotrexate or JAK inhibitors, have to be considered in future, to avoid steroid systemic side effects.
Significant repigmentation has been noted with use of two JAK kinase inhibitors tofacitinib and ruxolitinib. Afamelanotide, a synthetic alpha melanocyte-stimulating hormone which requires the presence of melanocortin 1 receptor and supplementation with NB-UVB to stimulate melanoblast differentiation, may be an effective new vitiligo therapy.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| Annexures|| |
Annexure 1: Vitiligo Area Severity Index
The percentage of vitiligo involvement is calculated in terms of hand units. One hand unit (which encompasses the palm plus the volar surface of all digits) is approximately equivalent to 1% of the total body surface area. The degree of pigmentation is estimated to the nearest of one of the following percentages: 100% – complete depigmentation, no pigment is present; 90% – specks of pigment present; 75% – depigmented area exceeds the pigmented area; 50% – pigmented and depigmented areas are equal; 25% – pigmented area exceeds depigmented area; and 10% – only specks of depigmentation present.
The VASI for each body region is determined by the product of the area of vitiligo in hand units and the extent of depigmentation within each hand unit measured patch.
The total VASI, with a score ranging from 0 to 100, is calculated using the formula: VASI = S (all body sites) (hand units) × (residual depigmentation).
Annexure 2: Vitiligo Disease Activity Score (VIDA)
The VIDA is a 6-point scale for assessing vitiligo activity. Scoring is based on the individual's own opinion of the present disease activity over time. Active vitiligo involves either expansion of existing lesions or appearance of new lesions. Grading is as follows: VIDA Score +4 – Activity of 6 weeks or less duration; +3 – Activity of 6 weeks to 3 months; +2 – Activity of 3–6 months; +1 – Activity of 6–12 months; 0 – Stable for 1 year or more; and - 1 – Stable with spontaneous repigmentation since 1 year or more. A low VIDA score indicates less activity.
| References|| |
Passeron T, Ortonne JP. Vitiligo and other disorders of hypopigmentation. In: Bolognia JL, Jorizzo JL, Schaffer JV, editors. Dermatology. 2nd
ed. Okhla: Elsevier; 2008. p. 1023-48.
Krüger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol 2012;51:1206-12.
Millington GW, Levell NJ. Vitiligo: The historical curse of depigmentation. Int J Dermatol 2007;46:990-5.
Nair BK. Vitiligo – A retrospect. Int J Dermatol 1978;17:755-7.
Silverberg NB. The epidemiology of vitiligo. Curr Derm Rep 2015;4:36-43.
Sehgal VN, Srivastava G. Vitiligo: Compendium of clinico-epidemiological features. Indian J Dermatol Venereol Leprol 2007;73:149-56.
] [Full text]
Liu JB, Li M, Yang S, Gui JP, Wang HY, Du WH, et al
. Clinical profiles of vitiligo in China: An analysis of 3742 patients. Clin Exp Dermatol 2005;30:327-31.
Fatani MI, AlSharif SH, Alfif KA, Khan AS, Hussain WA, Banjar AA. The clinical patterns of vitiligo “hospital-based study” in Makkah region, Saudi Arabia. J. Dermatol Dermatol surg 2014;18:17-21.
van Geel N, Speeckaert R, Taieb A, Picardo M, Böhm M, Gawkrodger DJ, et al
. Koebner's phenomenon in vitiligo: European position paper. Pigment Cell Melanoma Res 2011;24:564-73.
Passeron T, Ortonne JP. Physiopathology and genetics of vitiligo. J Autoimmun 2005;25 Suppl: 63-8.
Jin Y, Riccardi SL, Gowan K, Fain PR, Spritz RA. Fine-mapping of vitiligo susceptibility loci on chromosomes 7 and 9 and interactions with NLRP1 (NALP1). J Invest Dermatol 2010;130:774-83.
Yu HS. Melanocyte destruction and repigmentation in vitiligo: A model for nerve cell damage and regrowth. J Biomed Sci 2002;9:564-73.
Boissy RE, Spritz RA. Frontiers and controversies in the pathobiology of vitiligo: Separating the wheat from the chaff. Exp Dermatol 2009;18:583-5.
Parsad D, Kumaran M S. Depigmentary and hypopigmentary disorders. In: Sacchidanand S, editor. IADVL Textbook of Dermatology. 4th
ed. Mumbai: Bhalani; 2015. p. 1295.
Lotti T, Zanardelli M, D'Erme AM. Vitiligo: What's new in the psycho-neuro-endocrine-immune connection and related treatments. Wien Med Wochenschr 2014;164:278-85.
Arora AK, Kumaran MS. Pathogenesis of vitiligo: An update. Pigment Int 2017;4:65-77. [Full text]
Schallreuter KU, Moore J, Wood JM, Beazley WD, Peters EM, Marles LK, et al
. Epidermal H2O2 accumulation alters tetrahydrobiopterin (6BH4) recycling in vitiligo: Identification of a general mechanism in regulation of all 6BH4-dependent processes? J Invest Dermatol 2001;116:167-74.
Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: A comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol 2011;65:473-91.
Parsad D, Saini R, Verma N. Combination of PUVAsol and topical calcipotriol in vitiligo. Dermatology 1998;197:167-70.
Oh SH, Kim T, Jee H, Do JE, Lee JH. Combination treatment of non-segmental vitiligo with a 308-nm xenon chloride excimer laser and topical high-concentration tacalcitol: A prospective, single-blinded, paired, comparative study. J Am Acad Dermatol 2011;65:428-30.
AlGhamdi K, Kumar A, Moussa N. The role of vitamin D in melanogenesis with an emphasis on vitiligo. Indian J Dermatol Venereol Leprol 2013;79:750-8.
] [Full text]
Kumar R, Parsad D. Melanocytorrhagy and apoptosis in vitiligo: Connecting jigsaw pieces. Indian J Dermatol Venereol Leprol 2012;78:19-23.
] [Full text]
Njoo MD, Westerhof W. Vitiligo. Pathogenesis and treatment. Am J Clin Dermatol 2001;2:167-81.
Behl PN, Aggarwal A, Srivastava G. Vitiligo. In: Behl PN, Srivastava G, editors. Practice of. Dermatology. 9th
ed. New Delhi: CBS Publishers; 2003. p. 238-41.
Arata J, Abe-Matsuura Y. Generalized vitiligo preceded by a generalized figurate erythematosquamous eruption. J Dermatol 1994;21:438-41.
Goh BK, Pandya AG. Presentations, signs of activity, and differential diagnosis of vitiligo. Dermatol Clin 2017;35:135-44.
Ortonne JP, MacDonald DM, Micoudz A, Thivolet J. PUVA-induced repigmentation of vitiligo: A histochemical (split-DOPA) and ultrastructural study. Br J Dermatol 1979;101:1-12.
Hercogová J, Schwartz RA, Lotti TM. Classification of vitiligo: A challenging endeavor. Dermatol Ther 2012;25 Suppl 1:S10-6.
Koga M, Tango T. Clinical features and course of type A and type B vitiligo. Br J Dermatol 1988;118:223-8.
Hu F, Fosnaugh RP, Lesney PF.In vitro
studies on vitiligo. J Invest Dermatol 1959;33:267-80.
Hordinsky M, Ericson M. Autoimmunity: Alopecia areata. J Investig Dermatol Symp Proc 2004;9:73-8.
Hamzavi IH, Lim HW, Syed ZU. Ultraviolet-based therapy for vitiligo: What's new? Indian J Dermatol Venereol Leprol 2012;78:42-8.
] [Full text]
Garg BJ, Saraswat A, Bhatia A, Katare OP. Topical treatment in vitiligo and the potential uses of new drug delivery systems. Indian J Dermatol Venereol Leprol 2010;76:231-8.
] [Full text]
Morman MR. Possible side effects of topical steroids. Am Fam Physician 1981;23:171-4.
Lee JH, Kwon HS, Jung HM, Lee H, Kim GM, Yim HW, et al
. Treatment outcomes of topical calcineurin inhibitor therapy for patients with vitiligo: A systematic review and meta-analysis. JAMA Dermatol 2019;155:929-38.
Rai R, Srinivas CR. Phototherapy: An Indian perspective. Indian J Dermatol 2007;52:169-75. [Full text]
Mysore V, Shashikumar BM. Targeted phototherapy. Indian J Dermatol Venereol Leprol 2016;82:1-6.
] [Full text]
Kanwar AJ, Mahajan R, Parsad D. Low-dose oral mini-pulse dexamethasone therapy in progressive unstable vitiligo. J Cutan Med Surg 2013;17:259-68.
Mysore V, Koushik L. Overview of vitiligo surgery. In: Mysore V, editor. ACS(I) Textbook on Cutaneous and Aesthetic Surgery. Ch. 24A. New Delhi: Jaypee Brothers; 2017. p. 327-33.
Razmi T M, Afra TP, Parsad D. Vitiligo surgery: A journey from tissues via cells to the stems! Experim Dermatol 2019;28:690-4.
Koushik L. Autologous mini punch grafting in vitiligo. In: Mysore V, editor. ACS(I) Textbook on Cutaneous and Aesthetic Surgery. Ch. 24B. New Delhi: Jaypee Brothers; 2017. p. 334-42.
Benzekri L, Gauthier Y. Clinical markers of vitiligo activity. J Am Acad Dermatol 2017;76:856-62.
Kumar Jha A, Sothalia S, Lallas A, Chaudhary RK. Dermoscopy in vitiligo: diagnosis and beyond. Int J Dermatol 2018;57:50-4.
Nirmal B, Antonisamy B, Peter CV, George L, George AA, Dinesh GM. Cross-sectional study of dermatoscopic findings in relation to activity in vitiligo: BPLeFoSK criteria for stability. J Cutan Aesthet Surg 2019;12:36-41.
] [Full text]
Hanumanthaiah HC. Suction blister roof grafting. In: Mysore V, editor. ACS(I) Textbook on Cutaneous and Aesthetic Surgery. Ch. 24C. New Delhi: Jaypee Brothers; 2017. p. 345-50.
Khunger N, Kandhari R. Thin split thickness grafting for vitiligo. In: Mysore V, editor. ACS(I) Textbook on Cutaneous and Aesthetic Surgery. Ch. 24D. New Delhi: Jaypee Brothers; 2017. p. 351-8.
Khandapur S, Sharma VK, Manchanda Y. Comparison of mini punch grafting versus split thickness grafting in chronic stable vitiligo. Dermatol surg 2005; 31:436-4.
Ozdemir M, Cetinkale O, Wolf R, Kotoǧyan A, Mat C, Tüzün B, et al
. Comparison of two surgical approaches for treating vitiligo: A preliminary study. Int J Dermatol 2002;41:135-8.
Paul M. Epidermal non cultured cell suspension in vitiligo. In: Mysore V, editor. ACS(I) Textbook on Cutaneous and Aesthetic Surgery. Ch. 24E. New Delhi: Jaypee Brothers; 2017. p. 351-8.
Olsson MJ, Juhlin L. Leucoderma treated by transplantation of a basal cell layer enriched suspension. Br J Dermatol 1998;138:644-8.
van Geel N, Ongenae K, De Mil M, Naeyaert JM. Modified technique of autologous noncultured epidermal cell transplantation for repigmenting vitiligo: A pilot study. Dermatol Surg 2001;27:873-6.
Holla AP, Kumar R, Parsad D, Kanwar A. Modified procedure of noncultured epidermal suspension transplantation: Changes are the core of vitiligo surgery. J Cutan Aesthet Surg 2011;4:44-5.
] [Full text]
Mrigpuri S, Razmi T M, Sendhil Kumaran M, Vinay K, Srivastava N, Parsad D. Four compartment method as an efficacious and simplified technique for autologous non-cultured epidermal cell suspension preparation in vitiligo surgery: A randomized, active-controlled study. J Eur Acad Dermatol Venereol 2019;33:185-90.
Thakur V, Kumar S, Kumaran MS, et al
. Efficacy of transplantation of combination of Non cultured dermal and epidermal cell suspension vs. epidermal cell suspension alone in vitiligo: A randomized clinical trial. JAMA Dermatol 2019;155:204-10.
Boniface K, Seneschal J. Vitiligo as a skin memory disease: The need for early intervention with immunomodulating agents and a maintenance therapy to target resident memory T cells. Exp Dermatol 2019;28:656-61.
Nahhas AF, Braunberger TL, Hamzavi IH. Update on the Management of Vitiligo. Skin Therapy Lett 2019;24:1-6.
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6]